Transcatheter Versus Surgical Aortic Valve Replacement in Hypertrophic Cardiomyopathy Patients with Aortic Stenosis
Related Experiment Video
Updated: Sep 28, 2025

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
Mohammed Mhanna1, Abdul Mannan Khan Minhas2, Robert W Ariss3
1Department of Internal Medicine, The University of Toledo, Toledo, OH.
Insights
Transcatheter aortic valve replacement (TAVR) shows lower in-hospital mortality and fewer complications than surgical aortic valve replacement (SAVR) in hypertrophic cardiomyopathy patients with severe aortic stenosis. Further research on long-term outcomes is needed.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Interventional Cardiology
Background:
- Severe aortic stenosis (AS) is treated with surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).
- Patients with hypertrophic cardiomyopathy (HCM) were excluded from key TAVR trials, limiting comparative data.
- Understanding TAVR vs. SAVR outcomes in HCM patients with AS is crucial.
Purpose of the Study:
- To compare in-hospital outcomes and resource utilization between TAVR and SAVR in adult patients with HCM and severe AS.
- To evaluate the safety and efficacy of TAVR versus SAVR in this specific patient population.
Main Methods:
- Analysis of the 2016-2019 National Inpatient Sample database.
- Identification of adult hospitalizations with HCM undergoing SAVR or TAVR for severe AS.
- Comparison of primary (in-hospital mortality) and secondary outcomes, including complications and resource utilization.
Main Results:
- TAVR was associated with lower in-hospital mortality compared to SAVR in HCM patients with AS.
- TAVR demonstrated reduced rates of bleeding requiring transfusion, acute kidney injury, and shorter hospital stays.
- No significant differences were observed in cardiac arrest, new permanent pacemaker, or cardiac tamponade rates between TAVR and SAVR.
Conclusions:
- Transcatheter aortic valve replacement (TAVR) offers a lower-risk alternative to surgical aortic valve replacement (SAVR) for hypertrophic cardiomyopathy patients with isolated severe aortic stenosis.
- TAVR is linked to decreased in-hospital mortality, fewer peri-procedural complications, and improved resource utilization.
- Further investigation into the long-term efficacy and safety of TAVR versus SAVR in this cohort is warranted.
Abstract:
Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are well established treatment options for severe aortic stenosis (AS). However, patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal randomized controlled trials of TAVR vs SAVR. We queried the 2016 to 2019 National Inpatient Sample to identify adult hospitalizations with HCM who underwent SAVR or TAVR for severe AS. The primary outcome was in-hospital mortality. Secondary outcomes included cardiac arrest, new permanent pacemaker (PPM), cardiac tamponade, bleeding requiring transfusion, stroke/transient ischemic attack, acute kidney injury (AKI), and resource utilization (length of stay [LOS], hospital costs, and discharge to facility). Of 1245 HCM hospitalizations with severe AS, 595(47.8%) underwent TAVR and 650 (52.2%) underwent SAVR. In-hospital mortality rate was lower in the TAVR group. Cardiac arrest, cardiogenic shock, pressor use, new PPM, and cardiac tamponade were not significantly different between the 2 groups. When compared to SAVR, TAVR was associated with lower rates of bleeding requiring transfusion, vascular complications, AKI, and invasive mechanical ventilation. Furthermore, TAVR was associated with a shorter hospital stay, fewer facility discharges, but comparable hospital costs. Our findings indicate that TAVR is associated with lower risk of in-hospital mortality, certain peri-procedural complications, shorter hospital stay, and fewer facility discharges in HCM patients with isolated AS compared to SAVR. Further studies are needed to assess the mid- and long-term outcomes of TAVR vs SAVR in HCM patients with AS.
More Related Videos
12:17Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Mitral Stenosis III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care